Clinical	O
and	O
therapeutic	O
implications	O
of	O
BRAF	B:C1511021
mutation	I:C1511021
heterogeneity	O
in	O
metastatic	O
melanoma	I:C0278883
.	O

Clinical	O
and	O
therapeutic	O
implications	O
of	O
BRAF	O
mutation	I:C1511021
heterogeneity	O
in	O
metastatic	B:C0278883
melanoma	I:C0278883
.	O

Heterogeneity	O
of	O
BRAF	B:C1511021
mutation	I:C1511021
in	O
melanoma	O
has	O
been	O
a	O
controversial	O
subject	O
.	O

Heterogeneity	O
of	O
BRAF	O
mutation	I:C1511021
in	O
melanoma	B:C0278883
has	O
been	O
a	O
controversial	O
subject	O
.	O

Quantitative	O
data	O
on	O
BRAF	B:C0812241
allele	O
frequency	O
(	O
AF	O
)	O
are	O
sparse	O
,	O
and	O
the	O
potential	O
relationship	O
with	O
response	O
to	O
BRAF	O
inhibitors	I:C3838813
(	O
BRAF	O
inhibitors	I:C3838813
)	O
in	O
patients	O
with	O
metastatic	O
melanoma	I:C0278883
is	O
unknown	O
.	O

Quantitative	O
data	O
on	O
BRAF	O
allele	O
frequency	O
(	O
AF	O
)	O
are	O
sparse	O
,	O
and	O
the	O
potential	O
relationship	O
with	O
response	O
to	O
BRAF	B:C3838813
inhibitors	I:C3838813
(	O
BRAF	O
inhibitors	I:C3838813
)	O
in	O
patients	O
with	O
metastatic	O
melanoma	I:C0278883
is	O
unknown	O
.	O

Quantitative	O
data	O
on	O
BRAF	O
allele	O
frequency	O
(	O
AF	O
)	O
are	O
sparse	O
,	O
and	O
the	O
potential	O
relationship	O
with	O
response	O
to	O
BRAF	O
inhibitors	I:C3838813
(	O
BRAF	B:C3838813
inhibitors	I:C3838813
)	O
in	O
patients	O
with	O
metastatic	O
melanoma	I:C0278883
is	O
unknown	O
.	O

Quantitative	O
data	O
on	O
BRAF	O
allele	O
frequency	O
(	O
AF	O
)	O
are	O
sparse	O
,	O
and	O
the	O
potential	O
relationship	O
with	O
response	O
to	O
BRAF	O
inhibitors	I:C3838813
(	O
BRAF	O
inhibitors	I:C3838813
)	O
in	O
patients	O
with	O
metastatic	B:C0278883
melanoma	I:C0278883
is	O
unknown	O
.	O

We	O
quantitatively	O
measured	O
BRAF	B:C0812241
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	O
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAF	O
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	B:C0599755
of	O
treatment	O
naïve	O
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	O
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAF	O
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	B:C0278883
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	O
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAF	O
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	B:C2732543
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAF	O
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	O
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	B:C0087111
with	O
BRAF	O
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	O
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAF	B:C3838813
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	I:C0278883
melanoma	I:C0278883
samples	O
by	O
pyrosequencing	O
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAF	O
inhibitors	I:C3838813
as	O
part	O
of	O
their	O
clinical	O
care	B:C0086388
.	O

Fifty	O
-	O
two	O
samples	O
from	O
50	O
patients	O
were	O
analysed	B:C0936012
.	O

BRAF	B:C2698302
V600E	I:C2698302
mutations	I:C2698302
were	I:C2698302
detected	I:C2698302
in	O
71.1	O
%	O
of	O
samples	O
followed	O
by	O
V600	O
K	I:C2985121
(	O
25	O
%	O
)	O
and	O
V600R	O
(	O
3.9	O
%	O
)	O
.	O

BRAF	O
V600E	I:C2698302
mutations	I:C2698302
were	I:C2698302
detected	I:C2698302
in	O
71.1	O
%	O
of	O
samples	O
followed	O
by	O
V600	B:C2985121
K	I:C2985121
(	O
25	O
%	O
)	O
and	O
V600R	O
(	O
3.9	O
%	O
)	O
.	O

BRAF	O
V600E	I:C2698302
mutations	I:C2698302
were	I:C2698302
detected	I:C2698302
in	O
71.1	O
%	O
of	O
samples	O
followed	O
by	O
V600	O
K	I:C2985121
(	O
25	O
%	O
)	O
and	O
V600R	B:C0456984
(	O
3.9	O
%	O
)	O
.	O

There	O
was	O
a	O
wide	O
range	O
of	O
AF	O
from	O
3.9	O
%	O
to	O
80.3	O
%	O
(	O
median	B:C2939193
41.3	O
%	O
)	O
.	O

In	O
33	O
patients	O
treated	B:C0087111
with	O
BRAF	O
inhibitors	I:C3838813
,	O
there	O
was	O
no	O
difference	O
in	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
when	O
the	O
patients	O
were	O
categorized	O
into	O
high	O
or	O
low	O
AF	O
groups	O
.	O

In	O
33	O
patients	O
treated	O
with	O
BRAF	B:C3838813
inhibitors	I:C3838813
,	O
there	O
was	O
no	O
difference	O
in	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
when	O
the	O
patients	O
were	O
categorized	O
into	O
high	O
or	O
low	O
AF	O
groups	O
.	O

